| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 04/28/2005 | WO2004098492A3 Trans-golgi network-associated processes, methods and compositions related thereto |
| 04/28/2005 | WO2004093817A3 Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| 04/28/2005 | WO2004089303A3 Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| 04/28/2005 | WO2004089293A3 Hydroxamic acid compounds and methods of use thereof |
| 04/28/2005 | WO2004089279A3 Long-acting derivatives of pyy agonists |
| 04/28/2005 | WO2004080384A3 Method of treating chronic joint pain |
| 04/28/2005 | WO2004075826A3 Extended release, multiple unit dosage forms of phenytoin sodium and processes for their preparation |
| 04/28/2005 | WO2004073630A3 Anti-angiogenic and anti-tumoral properties of beta and gamma secretase inhibitors |
| 04/28/2005 | WO2004071437A3 Compositions for enhancing sexual responsiveness |
| 04/28/2005 | WO2004064784A3 Composition and method for preventing or treating a virus infection |
| 04/28/2005 | WO2004064765A3 Herpesvirus amplicon particles |
| 04/28/2005 | WO2004064759A3 Use of tryptanthrin compounds for immune potentiation |
| 04/28/2005 | WO2004062587A3 Night-time oral insulin therapy |
| 04/28/2005 | WO2004050034A3 Prolonged suppression of electrical activity in excitable tissues |
| 04/28/2005 | WO2004041846A3 INDUCIBLE LIGAND FOR α1β1 INTEGRIN AND USES |
| 04/28/2005 | WO2004035000A3 Enhancement of sleep with t-type calcium channel antagonists |
| 04/28/2005 | WO2004032839A3 Methods and formulations comprising agonists and antagonists of nuclear hormone receptors |
| 04/28/2005 | US20050090722 Method and apparatus for providing UV light to blood |
| 04/28/2005 | US20050090557 Methods and compositions for administration of TRPV1 agonists |
| 04/28/2005 | US20050090517 Pharmaceutical combinations of cox-2 inhibitors and opiates |
| 04/28/2005 | US20050090505 Methods of reducing risk of infection from pathogens |
| 04/28/2005 | US20050090467 administering 4-thiouridine, isomaltitol and uridine as antiinflammatory agents and/or problems in hemostasis related to platelet function |
| 04/28/2005 | US20050090455 for prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. |
| 04/28/2005 | US20050089957 Chimera; immunoglobuins; antibodies; host cells; immunohistochemistry |
| 04/28/2005 | US20050089586 Extract of acanthopanax koreanum for the treatment or prevention of hepatitis or the liver protective drug |
| 04/28/2005 | US20050089573 Oral pharmaceutical formulation containing ibandronate |
| 04/28/2005 | US20050089568 Melt-extruded orally administrable opioid formulations |
| 04/28/2005 | US20050089521 Methods for treating taxol-induced sensory neuropathy |
| 04/28/2005 | US20050089478 Formeratol and budesonide for treatment of respiratory system disorders such as chronc obstructive pulmonary disease |
| 04/28/2005 | US20050089477 Medicaments |
| 04/28/2005 | US20050089473 By administering one or more activators of an ATP-sensitive potassium channel in combination with one or more activators of a calcium-activated potassium channel to increase permeability of the drugs through the capillaries in the abnormal brain tissue |
| 04/28/2005 | US20050086748 Quaternized N-heterocyclic direct dye and aminated silicones, the polyoxyalkylenated silicones, the silicone gums and resins; hair dyes; colorfastness, weatherproof, uniformity |
| 04/28/2005 | CA2762955A1 Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
| 04/28/2005 | CA2546623A1 Cystatin c as an antagonist of tgf-.beta. and methods related thereto |
| 04/28/2005 | CA2542638A1 Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
| 04/28/2005 | CA2542636A1 Muscarinic acetylcholine receptor antagonists field of the invention |
| 04/28/2005 | CA2542634A1 Disinfecting teat care compositions |
| 04/28/2005 | CA2542631A1 Listeria-based epha2 vaccines |
| 04/28/2005 | CA2542629A1 Ntrk1 genetic markers associated with age of onset of alzheimer's disease |
| 04/28/2005 | CA2542417A1 Methods and compositions for the treatment of neurological disease |
| 04/28/2005 | CA2542084A1 A method for the separation anti-amyloid beta antibody with amyloid beta peptide |
| 04/28/2005 | CA2541847A1 Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
| 04/28/2005 | CA2541425A1 Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
| 04/28/2005 | CA2540623A1 Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischenic mediated central nervous system disorders or injury |
| 04/28/2005 | CA2539755A1 Alkanol and cycloalkanol-amine derivatives and methods of their use |
| 04/28/2005 | CA2538722A1 Expression of dominant negative transmembrane receptors in the milk of transgenic animals |
| 04/28/2005 | CA2537900A1 Multiplex vaccines |
| 04/27/2005 | EP1526174A2 Compositions comprising viruses and methods for concentrating virus preparations |
| 04/27/2005 | EP1526173A2 Compositions comprising viruses and methods for concentrating virus preparations |
| 04/27/2005 | EP1526130A1 Substituted isoquinolines as ultra short acting neuromuscular blockers |
| 04/27/2005 | EP1525473A2 Method and device for protein delivery into cells |
| 04/27/2005 | EP1525207A2 Process for purification of zoledronic acid |
| 04/27/2005 | EP1419150B1 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 04/27/2005 | EP0939818B1 Recombinant toxin fragments |
| 04/27/2005 | CN1610679A Efficient process for the preparation of a factor XA inhibitor |
| 04/27/2005 | CN1610549A Epermycin derivative for treating difficult to cure tumor |
| 04/27/2005 | CN1610538A Microemulsion preconcentrate |
| 04/27/2005 | CN1198832C New amino propylphosphinic acid |
| 04/27/2005 | CN1198818C Compound with growth hormone releasing properties |
| 04/27/2005 | CN1198813C Benzofuran derivatives their preparation and use |
| 04/27/2005 | CN1198622C Steroidal saponins for treating alzheimer's disease and derivatives thereof |
| 04/27/2005 | CN1198607C Composition for treating or preventing glomerulopathy |
| 04/27/2005 | CN1198597C Stable pharmaceutical formulation comprising HMC-CoA reductase inhibitor |
| 04/27/2005 | CN1198578C 皮肤护理组合物 Skin care compositions |
| 04/27/2005 | CN1198571C Oxidising composition and uses for keratin fibre dyeing, permanently deforming or bleaching |
| 04/26/2005 | US6883521 Method and apparatus for dosing single and multi-agent therapy |
| 04/21/2005 | WO2005035731A2 Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists |
| 04/21/2005 | WO2005034883A2 A method of healing skin wounds in mammals and a composition therefor |
| 04/21/2005 | WO2005034881A2 Methods and compositions for treating conditions involving abnormal angiogenesis |
| 04/21/2005 | WO2005034880A2 Thiophene and benzothiophene hydroxamic acid derivatives |
| 04/21/2005 | WO2005034879A2 Treatment of diseases involving erbb2 kinase overexpression |
| 04/21/2005 | WO2005034878A2 Pyrovalerone analogs and therapeutic uses thereof |
| 04/21/2005 | WO2005034877A2 G-csf transferrin fusion proteins |
| 04/21/2005 | WO2005034876A2 Use of cell lines to produce active therapeutic proteins |
| 04/21/2005 | WO2005034874A2 Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications |
| 04/21/2005 | WO2005034873A2 A method for reducing anti-neoplastic agent induced side-effects |
| 04/21/2005 | WO2005034871A2 Methods for treating diseases and conditions with inverse agonists |
| 04/21/2005 | WO2005034869A2 Compounds and compositions as protein kinase inhibitors |
| 04/21/2005 | WO2005034867A2 Thioether-substituted benzamides as inhibitors of factor xa |
| 04/21/2005 | WO2005034866A2 Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors |
| 04/21/2005 | WO2005034865A2 Water-soluble chitosan having low endotoxin concentration and methods for making and using the same |
| 04/21/2005 | WO2005034864A2 Spine replacement system |
| 04/21/2005 | WO2005034863A2 Countermeasures against malaria |
| 04/21/2005 | WO2005034862A2 Topical composition |
| 04/21/2005 | WO2005034861A2 A dried biotherapeutic composition, uses, and device and methods for administration thereof |
| 04/21/2005 | WO2005034860A2 Thiol reactive agents as a therapeutic modality |
| 04/21/2005 | WO2005034857A2 Methods and compositions comprising diamines as new anti-tubercular therapeutics |
| 04/21/2005 | WO2005034856A2 Targeted drug-formaldehyde conjugates and methods of making and using the same |
| 04/21/2005 | WO2005034855A2 Photodynamic inactivation of bacterial spores |
| 04/21/2005 | WO2005034853A2 Uses of interferons with altered spatial structure |
| 04/21/2005 | WO2005034852A2 Protein biomaterials and biocoacervates and methods of making and using thereof |
| 04/21/2005 | WO2005034851A2 Method and apparatus for providing uv light to blood |
| 04/21/2005 | WO2005034848A2 Inhibitors of cathepsin s |
| 04/21/2005 | WO2005034847A2 Methods of reducing risk of infection from pathogens |
| 04/21/2005 | WO2005034846A2 Withanamide and withanolide compositions and method of use thereof |
| 04/21/2005 | WO2005034844A2 Exosite-directed thrombin inhibitors |
| 04/21/2005 | WO2005034843A2 Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders |
| 04/21/2005 | WO2005034842A2 Peptides useful as hiv fusion inhibitors |
| 04/21/2005 | WO2005034841A2 Anthrax vaccine |
| 04/21/2005 | WO2005034838A2 Protease inhibitors |